MGO One Seven’s Moderna MRNA Stock Holding History

MGO One Seven’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,200	Closed	-$124K	–	942
2023 Q3	$124K	Buy	+1,200	New	+$134K	0.01%	787

Other funds holding MRNA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

MGO One Seven's MRNA Position: Q4 2024 in Review

MGO One Seven sold out of Moderna (MRNA) in Q4 2024, closing a stake of 3,051 shares — an estimated $204K sold.

MGO One Seven first reported a position in MRNA in Q2 2021 and held it in 7 quarters. The position peaked at $401K in Q2 2024. 745 funds tracked by Wall St. Rank hold MRNA as of Q4 2024.

MGO One Seven reported no remaining Moderna position as of Q4 2024 after selling out during the quarter.
MGO One Seven sold 3,051 Moderna shares in Q4 2024, an estimated $204K.
MGO One Seven first reported a position in Moderna in Q2 2021 and held it in 7 quarters.
MGO One Seven's Moderna position peaked at $401K in Q2 2024.
745 funds tracked by Wall St. Rank held Moderna as of Q4 2024.

Based on MGO One Seven's 13F filing for Q4 2024, filed 14 Feb 2025.